Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Recent studies identified a short peptide motif that serves as a docking site for cyclin/cyclin-dependent kinase (cdk) 2 complexes . Peptides containing this motif block the phosphorylation of substrates by cyclin A/cdk2 or cyclin E/cdk2. Here we report that cell membrane-permeable forms of such peptides preferentially induced transformed cells to undergo apoptosis relative to nontransformed cells. Deregulation of E2F family transcription factors is a common event during transformation and was sufficient to sensitize cells to the cyclin/cdk2 inhibitory peptides. These results suggest that deregulation of E2F and inhibition of cdk2 are synthetically lethal and provide a rationale for the development of cdk2 antagonists as antineoplastic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line.
Boukamp, P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A., & Fusenig, N. E. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.3.761 · Cited by 4,170
Tat-mediated delivery of heterologous proteins into cells.
Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B., & Barsoum, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.664 · Cited by 1,225
Expression of transcription factor E2F1 induces quiescent cells to enter S phase
Johnson, D. G., Schwarz, J. K., Cress, W. D., & Nevins, J. R. (1993) · Nature · doi:10.1038/365349a0 · Cited by 943
Nagahara, H., Vocero-Akbani, A. M., Snyder, E. L., Ho, A., Latham, D. G., Lissy, N. A., Becker-Hapak, M., Ezhevsky, S. A., & Dowdy, S. F. (1998) · Nature Medicine · doi:10.1038/4042 · Cited by 928
Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex
Russo, A. A., Jeffrey, P. D., Patten, A. K., Massagué, J., & Pavletich, N. P. (1996) · Nature · doi:10.1038/382325a0 · Cited by 907
p53 and E2F-1 cooperate to mediate apoptosis.
Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 839
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
Qin, X. Q., Livingston, D. M., Kaelin, W. G., & Adams, P. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10918 · Cited by 756
Self-citationDeregulated expression of E2F-1 induces S-phase entry and leads to apoptosis.
Shan, B., & Lee, W. H. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8166 · Cited by 530
Johnson, D. G., Ohtani, K., & Nevins, J. R. (1994) · Genes & Development · doi:10.1101/gad.8.13.1514 · Cited by 494
Cited by
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“(Chen et al., 1999), which might show particular promise in tumors with elevated E2F activity (Figure 3).”
BackgroundTo cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Self-citationGreen, D. R., & Evan, G. I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00024-7 · Cited by 1,254
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
A peptide carrier for the delivery of biologically active proteins into mammalian cells
Morris, M. C., Depollier, J., Mery, J., Heitz, F., & Divita, G. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1173 · Cited by 1,018
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Pucci, B., Kasten, M., & Giordano, A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900101 · Cited by 652
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Protein transduction: unrestricted delivery into all cells?
Schwarze, S. R., Hruska, K. A., & Dowdy, S. F. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01771-2 · Cited by 552
Brown, N. R., Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (1999) · Nature Cell Biology · doi:10.1038/15674 · Cited by 546
Cyclin E in normal and neoplastic cell cycles
Hwang, H. C., & Clurman, B. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208613 · Cited by 514
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Protein transduction technology
Wadia, J. S., & Dowdy, S. F. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00284-7 · Cited by 483
Delivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Schwarze, S. R., & Dowdy, S. F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01429-7 · Cited by 452
WADIA, J., & DOWDY, S. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.005 · Cited by 428
McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10738 · Cited by 364
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Rational design of shepherdin, a novel anticancer agent
Plescia, J., Salz, W., Xia, F., Pennati, M., Zaffaroni, N., Daidone, M. G., Meli, M., Dohi, T., Fortugno, P., Nefedova, Y., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.035 · Cited by 341
The dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
The genetics of the E2F family of transcription factors: shared functions and unique roles
DeGregori, J. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00051-3 · Cited by 295
In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein
Krosl, J., Austin, P., Beslu, N., Kroon, E., Humphries, R. K., & Sauvageau, G. (2003) · Nature Medicine · doi:10.1038/nm951 · Cited by 283
T Antigens of Simian Virus 40: Molecular Chaperones for Viral Replication and Tumorigenesis
Sullivan, C. S., & Pipas, J. M. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.2.179-202.2002 · Cited by 258
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Metadata
- Authors
- Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-04-13
- Volume
- 96
- Issue
- 8
- Pages
- 4325-4329
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2025618547
- Cited by
- 314
- References
- 31
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.